Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).

Title

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).

Authors

Keywords

-

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 28, Issue 15_suppl, Pages 3501-3501

Publisher

American Society of Clinical Oncology (ASCO)

Online

2017-02-24

DOI

10.1200/jco.2010.28.15_suppl.3501